Literature DB >> 12816998

Peroxisome proliferator-activated receptor alpha negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation.

Dallas C Jones1, Xiaohong Ding, Tian Y Zhang, Raymond A Daynes.   

Abstract

Expression of the nuclear hormone receptor peroxisome proliferator-activated receptor alpha (PPARalpha) in resting lymphocytes was recently established, although the physiologic role(s) played by this nuclear hormone receptor in these cell types remains unresolved. In this study, we used CD4(+) T cells isolated from PPARalpha(-/-) and wild-type mice, as well as cell lines that constitutively express PPARalpha, in experiments designed to evaluate the role of this hormone receptor in the regulation of T cell function. We report that activated CD4(+) T cells lacking PPARalpha produce increased levels of IFN-gamma, but significantly lower levels of IL-2 when compared with activated wild-type CD4(+) T cells. Furthermore, we demonstrate that PPARalpha regulates the expression of these cytokines by CD4(+) T cells in part, through its ability to negatively regulate the transcription of T-bet. The induction of T-bet expression in CD4(+) T cells was determined to be positively influenced by p38 mitogen-activated protein (MAP) kinase activation, and the presence of unliganded PPARalpha effectively suppressed the phosphorylation of p38 MAP kinase. The activation of PPARalpha with highly specific ligands relaxed its capacity to suppress p38 MAP kinase phosphorylation and promoted T-bet expression. These results demonstrate a novel DNA-binding independent and agonist-controlled regulatory influence by the nuclear hormone receptor PPARalpha.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12816998     DOI: 10.4049/jimmunol.171.1.196

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  PPAR-alpha in cutaneous inflammation.

Authors:  Sandrine Dubrac; Matthias Schmuth
Journal:  Dermatoendocrinol       Date:  2011-01

2.  Peroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way.

Authors:  Monan Angela Zhang; Dorothy Rego; Marina Moshkova; Hania Kebir; Andrzej Chruscinski; Hoangkim Nguyen; Rainer Akkermann; Frank Z Stanczyk; Alexandre Prat; Lawrence Steinman; Shannon E Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-30       Impact factor: 11.205

Review 3.  PPARs and molecular mechanisms of transrepression.

Authors:  Mercedes Ricote; Christopher K Glass
Journal:  Biochim Biophys Acta       Date:  2007-03-12

Review 4.  Lipid-lowering drugs.

Authors:  K Pahan
Journal:  Cell Mol Life Sci       Date:  2006-05       Impact factor: 9.261

5.  Diverse inflammatory cytokines induce selectin ligand expression on murine CD4 T cells via p38α MAPK.

Authors:  Mark E Ebel; Olufolakemi Awe; Mark H Kaplan; Geoffrey S Kansas
Journal:  J Immunol       Date:  2015-05-04       Impact factor: 5.422

6.  Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease.

Authors:  Anne R Gocke; Rehana Z Hussain; Yuhong Yang; Haiyan Peng; Jeffrey Weiner; Li-Hong Ben; Paul D Drew; Olaf Stuve; Amy E Lovett-Racke; Michael K Racke
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

7.  PPARalpha is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesis.

Authors:  Tarek Benameur; Simon Tual-Chalot; Ramaroson Andriantsitohaina; María Carmen Martínez
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

8.  Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity.

Authors:  Shannon E Dunn; Roopa Bhat; Daniel S Straus; Raymond A Sobel; Robert Axtell; Amanda Johnson; Kim Nguyen; Lata Mukundan; Marina Moshkova; Jason C Dugas; Ajay Chawla; Lawrence Steinman
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 17.579

Review 9.  Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis.

Authors:  Michael K Racke; Anne R Gocke; Mark Muir; Asim Diab; Paul D Drew; Amy E Lovett-Racke
Journal:  J Nutr       Date:  2006-03       Impact factor: 4.798

10.  Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-gamma production in mice.

Authors:  Rajkumar Noubade; Graeme Milligan; James F Zachary; Elizabeth P Blankenhorn; Roxana del Rio; Mercedes Rincon; Cory Teuscher
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.